Xilio Therapeutics (XLO) Cash from Investing Activities (2020 - 2026)
Xilio Therapeutics (XLO) reported Cash from Investing Activities of -$556000.0 for Q1 2026, down 2427.27% on a YoY basis from $23890.6 in Q1 2025, and down 485.26% sequentially from -$95000.0 in Q4 2025.
Xilio Therapeutics (XLO) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Cash from Investing Activities data on file, last reported at -$556000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 2427.27% year-over-year to -$556000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.1 million (down 2743.24% YoY), and the FY2025 full-year result was -$518000.0, down 1338.89% from the prior year.
- Cash from Investing Activities retreated to -$556000.0 in Q1 2026, from -$95000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$6000.0 in Q4 2024 to a low of -$771000.0 in Q2 2022.
- A 5-year average of -$286833.3 and a median of -$285000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities soared 59.01% in 2023 and sank 2427.27% in 2026, its largest moves.
- Tracing XLO's Cash from Investing Activities over 5 years: stood at -$509000.0 in 2022, then jumped by 37.92% to -$316000.0 in 2023, then jumped by 98.1% to -$6000.0 in 2024, then slumped by 1483.33% to -$95000.0 in 2025, then sank by 485.26% to -$556000.0 in 2026.
- Business Quant data shows XLO's Cash from Investing Activities at -$556000.0 in Q1 2026, -$95000.0 in Q4 2025, and -$401000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -556,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2026 | -556,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Jun 30, 2025 | -401,000.00 |
| Jun 30, 2025 | -401,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2023 | -316,000.00 |
| Jun 30, 2023 | -316,000.00 |
| Mar 31, 2023 | -170,000.00 |
| Mar 31, 2023 | -170,000.00 |
| Dec 31, 2022 | -509,000.00 |
| Dec 31, 2022 | -509,000.00 |
| Sep 30, 2022 | -333,000.00 |
| Sep 30, 2022 | -333,000.00 |